HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours By Ogkologos - July 30, 2025 453 0 Facebook Twitter Google+ Pinterest WhatsApp Real-world experience from pan-tumour testing Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Mom Says Family Was Kicked Out Of Movie Theater Because Her... April 19, 2019 Hyperfractionated Intensity-Modulated Radiotherapy Decreases the Rate of Severe Late Complications and... March 7, 2023 Pembrolizumab Combinations Show Promise in mCRPC November 21, 2020 A new year of expanding research horizons January 21, 2022 Load more HOT NEWS Approximately 1 Million of New Maternal Orphans Due to Cancer in... How to Find an Oncologist Who’s an LGBTQ+ Ally: An Expert... Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated... FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma...
